Now showing items 1-1 of 1

    • IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. 

      Calcinotto, A; Spataro, C; Zagato, E; Di Mitri, D; Gil, V; Crespo, M; De Bernardis, G; Losa, M; Mirenda, M; Pasquini, E; Rinaldi, A; Sumanasuriya, S; Lambros, MB; Neeb, A; Lucianò, R; Bravi, CA; Nava-Rodrigues, D; Dolling, D; Prayer-Galetti, T; Ferreira, A; Briganti, A; Esposito, A; Barry, S; Yuan, W; Sharp, A; de Bono, J; Alimonti, A (2018-07)
      Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a condition known as castration-resistant prostate cancer (CRPC). Acquiring a better understanding of the mechanisms that control ...